The Drug Facts Box: Providing Consumers with Simple Tabular Data on Drug Benefit and Harm

Abstract

Context. Direct-to-consumer drug ads have been criticized for providing inadequate and misleading information. Requiring ads to include a table with data on drug benefits and side effects (derived from clinical trials) could help, provided that consumers understand such tabular information. Objective. To determine if people could understand and use a 9-row × 2-column ``study findings table'' presenting expected outcomes (both beneficial and harmful) with and without a drug. Subjects.A convenience sample of 274 participants: 186 recruited from alumni of Dartmouth's ``Community Medical School'' public lecture series and Dartmouth Hitchcock's Center for Shared Decision Making and 88 veterans and their families recruited from waiting rooms in the Veterans Affairs outpatient clinic, White River Junction, Vermont. Design. Cross-sectional survey. Participants were tested on their comprehension of the study findings table about the drug tamoxifen used for the primary prevention of breast cancer—with no instructions on how to use the table. Main outcome measure. Five comprehension questions testing how well participants could read and use the table with drug benefits and side effects data. Results. On average, participants correctly answered 4 of the 5 table comprehension questions: 89% correctly used the table to determine the percentage of womengiventamoxifenwhogotabloodclotintheirlegsor lungs, and 71% were able to use data in the table to calculate the absolute difference in the proportion of women who got breast cancer in the tamoxifen v. the placebo group. Most participants were also able to use the table to make comparisons. Conclusion. Most participants—even those with lower formal educational attainment—were able to understand and use the tabular data.

Keywords

Key words: risk communication decision aids pharmaceutical decision making. (Med Decis Making 2007;27:655—662)

Get full access to this article

View all access options for this article.

References

Bell R. , Wilkes M. , Kravitz R. The educational value of consumer-target prescription drug print advertising . J Fam Pract. 2000;49:1092—8.

Woloshin S. , Schwartz L. , Tremmel J. , Welch H.

Direct to consumer drug advertisements: what are Americans being sold?

Lancet. 2001;358:1141—6.

Waxman H. Ensuring that consumers receive appropriate information from drug ads: what is the FDA's role? Health Aff (Millwood). 2004 Jan—Jun;Suppl Web Exclusives:W4256—8.

Gazmararian JA , Baker DW , Williams MW , et al. Health literacy among Medicare enrollees in a managed care organization. JAMA. 1999 ;281:545—51.

Kirsch IS , Jungeblut A. , Jenkins L. , Kolstad A. Adult Literacy in America. Washington, DC: National Center for Education Statistics; 1993.

Schwartz LM , Woloshin S. , Black WC , Welch HG The role of numeracy in understanding the benefit of screening mammography . Ann Intern Med. 1997;127:966—72.

Woloshin S. , Schwartz L. , Welch H. The value of benefit data in direct-to-consumer drug ads. Health Aff (Millwood). 2004 Jan— Jun;Suppl Web Exclusives:W234—45.

ZENECA Pharmaceuticals. Professional information brochure: Nolvadex (tamoxifen citrate); 1998. Available from: http:// www.fda.gov/cder/foi/label/1998/17970.pdf

Fisher B. , Costantino J. , Wickerman D. , et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90: 1371—88.

10.

Dartmouth Community Medical School. Available from: http://dms.dartmouth.edu/dcms.

11.

Gigerenzer G. , Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ. 2003;327:741—4.

12.

Schwartz L. , Woloshin S. , Welch H. Know Your Chances: Understanding Health Statistics. White River Junction, VT: VA Outcomes Group; 2005.

13.

Lipkus I. , Samsa G. , Rimer B. General performance on a numeracy scale among highly educated samples. Med Decis Making. 2001;21:37—44.

14.

Woloshin S. , Schwartz LM , Welch HG The effectiveness of a primer to help people understand risk: Two randomized trials in distinct populations. Annals Intern Med. 2007;146:256—65.